SEC Tracker
Get the app

Rigel Pharmaceuticals RIGL

Rigel Pharmaceuticals: quarterly report for the quarter ended Mar 31, 2021

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Rigel Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Amarin AMRN public float $335M, Jun 30, 2025
  2. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  3. Altimmune ALT public float $327M, Jun 30, 2025
  4. Prothena PRTA public float $327M, Jun 30, 2025
  5. Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.